Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 282791

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Therapeutic
  • Delivery
  • Gastrointestinal

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282791

License Grant
The original agreement for commercialization of ConsensiTM in the U.S has been amended to include creating a near-term revenue streams to support further development of our oncology pipeline, engage a distribution partner with an established sales network and access to thousands of pharmacies to drive the launch of the drug.  In addition, a marketing plan and pricing strategy have been finalized.
License Property
Licensor is a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance.

ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

Field of Use
The Indications and Usage for Consensiâ„¢ is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions.

IPSCIO Record ID: 234734

License Grant
The Israel Licensor granted exclusive rights to import, manufacture and distribute its lead drug candidate, Consensiâ„¢, in China to the Chinese Licensee.
License Property
Consensi™, formerly known as KIT-302, is a combination drug intended to simultaneously treat pain caused by osteoarthritis, and hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain. Consensi™ is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 28187

License Grant
The Licensor transferred the development and commercialization rights of Prestalia to the Licensee.
License Property
Prestalia® contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension, to lower blood pressure.
Field of Use
On January 26, 2015, the Licensee announced that the FDA approved Prestalia (perindopril arginine and amlodipine) tablets for the treatment of hypertension.

IPSCIO Record ID: 27649

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses under the licensed technology to make, use, have made, sell, offer for sale, import and export products.

Licensor grants a license to use the house marks in connection with the commercialization of the products.

License Property
The licensed technology is US patent 6926907 and filed patent serial no. 11/129,320, pharmaceutical compositions for the coordinated delivery of NSAIDs.

NSAID means any non-steroidal anti-inflammatory drug, the primary mechanism of action of which is inhibition of cyclooxygenase, but excluding acetyl salicylic acid.

Field of Use
The field of use is the treatment of human diseases and conditions by means of a pharmaceutical product.

IPSCIO Record ID: 260459

License Grant
Licensor grants to the Licensee of Sweden an exclusive license, with the right to grant sublicenses, under the Licensed Technology to make, use, have made, sell, offer for sale, import, and export Products in the Field of Use in the Territory.

Licensor grants a license to use the Licensor House Marks in connection with the Commercialization of Licensor Products in the Field of Use in the Territory.

Licensor grants an option for a period of twenty-four months the Japan Option Period after the Effective Date to include Japan in the Territory to Licensee.

License Property
Licensors Product means any product that combines a Gastroprotective Agent and any NSAID in a single fixed combination dosage form, that would, if made, used, sold, offered for sale, had made, imported or exported without a license from Licensor of the Licensed Patents, infringe one or more Valid Claims of the Licensed Patents.

Esomeprazole means that certain pharmaceutical compound with the name (5-methoxy-2-{(S)-[ ( 4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl }-1 H-benzimidazole ), including any salts, hydrates, solvates, polymorphs and tautomers thereof.

Naproxen means that certain pharmaceutical compound with the chemical name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneaceti,c acid, including any esters, salts, hydrates, solvates and polymorphs thereof.

The patent is for Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs.

Field of Use
Field of Use means the treatment of human diseases and conditions by means of a pharmaceutical product.  These Pharmaceutical Compositions are for the Coordinated Delivery of NSAIDs.

IP relates to the sublicenses’s proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet.  Naproxen is used to relieve pain from various conditions such as headache, muscle aches, tendonitis, dental pain, and menstrual cramps. It also reduces pain, swelling, and joint stiffness caused by arthritis, bursitis, and gout attacks. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).

IPSCIO Record ID: 26321

License Grant
The Licensor signed a License Agreement with the Licensee for Indaflex.

Under the terms of the Agreement executed the Licensor could receive up to $116 million in milestone payments on achievement of all regulatory and revenue targets. In addition the Licensee assumes all clinical and commercialization costs, in return for full commercialization and sub-licensing rights in the U.S and other regions.

License Property
Indaflex(TM) is topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended to start clinical development soon for use in the treatment symptoms of arthritis.  The product is currently in Phase II clinical development for the reduction of signs and symptoms associated with osteoarthritis of the knee.

Indaflexâ„¢ Cream is a semi-solid formulation for topical administration, containing the active ingredient Indomethacin, at a concentration of 2.5%. Indaflexâ„¢ Cream is an innovative oil-in-water emulsion formulation. There are three main features of this product which contribute to its improved efficacy as a topical analgesic: drug loading/concentration, a nanoparticulate oil-in-water emulsion formulation and an improved partitioning of lipophilic drug from nanoparticles into the lipid matrix of the absorbing tissue.

Indaflexâ„¢ Cream is composed of a highly dispersed colloidal suspension of nano-sized oil droplets, loaded with active drug and suspended in an aqueous phase.

Field of Use
Indaflex is a non-steroidal anti-inflammatory drug, typically prescribed in order to manage symptoms such as pain, fever, swelling and stiffness. This medication acts as an inhibitor of prostaglandin production – prostaglandins are the agents that are known to induce these symptoms.

IPSCIO Record ID: 32573

License Grant
The Licensor grants the Licensee an exclusive license under the Licensed Patents and Know-How to develop and to make, have made, use, sell, have sold and otherwise dispose of the Licensed Product, a pharmaceutical used for pain.
License Property
The Licensor owns or controls the rights to a proprietary drug product –  the combination of celecoxib and dextromethorphan or any combination that includes celecoxib or dextromethorphan to treat neurological disorders and pain.
Field of Use
The Licensee is a biopharmaceutical research and development company. The Licensee shall be entitled to certain rights to develop and commercialize the Licensed Product.
The Field is limited to, veterinary and human therapeutic and diagnostic products and the manufacture, use and sale thereof.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.